Our findings support the paradigm that TLR4 represents a novel target for the treatment of insulin resistance and that TLR4 inhibitors could be useful therapeutics in the management of obesity-related metabolic disease. Here, TLR4 is linked to obesity due to melanocortin 4 receptor deficiency.